Genmab — November 2018

[gentogen]

I tillægsaftalen fra 2010 hedder det, at "Genmab will forego development milestones for autoimmune indications and the first two sales milestones while retaining a double digit royalty on sales"

[bibob]

Lidt fra " Tante Berlinger " https://www.berlingske.dk/www.berlingske.dk/tre-scenarier-for-aktiemarkederne-efter-det-amerikanske

[Bella1]

"med livrem og seler:-)

[E_L]

I can't remember if this Teprotumumab update was posted http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-announces-presentation-results-48-week?_ga=2.118113481.1921129680.1541499979-967984457.1541499979

[E_L]

"The analysis of this Phase 2 exploratory endpoint shows that 69.2percent (18/26 patients) of those with diplopia improvements of at leastone grade at week 24 maintained these improvements at week 72 (48 weeksfollowing treatment period)."

[Helge_LarsenPI-redaktør]

"I think it is worth highlighting Genmab as a company that has made it all the way – and in my view has been very successful in bringing a product to the market and has developed into a company with a lot of attention – also generalist investors. Due to its size it has meant a lot in shaping a market for biotechs in the Nordics and proven that it can be done" . http://app.n.nasdaq.com/e/es?s=1981692173&e=82533&elqTrackId=779951e9dfa7432ab00e909c98de7ed0&elq=294d18ca9aee40aeae7b9bd1bf0d9ee8&elqai

[henrik48]

Berettiget ros til Genmab

[peter12]

SITC har frigivet abstracts i dag og dara bliver nævnt ifm CLL https://www.sitcancer.org/2018/abstracts/titles

[gentogen]

Angående tidligere: International Immunology, Volume 30, Issue 8, 24 July 2018, Pages 375–383: the combination of ATRA and DARA has potent anti-leukemic effects, mediated through CD38 up-regulation and antibody-induced fratricide, in vitro and in vivo. Indeed, within the murine models, combination treatment led to reduced tumor size and growth rate and a 46.6% increase in mean survival time

[gentogen]

ATRA appears to be a strong enhancer of anti-CD38 antibody therapy for AML in vivo

[gentogen]

the significant survival advantage resulting from the combination treatment of ATRA and DARA suggests that ATRA does make the AML blasts more targetable by anti-CD38 DARA.

[peter12]

Der er også et par nye? GEN1042 og GEN1046 nævnt i SITC abstracts

[E_L]

@gentogen 1 of the forum members a while ago mentioned ATRA being rather toxic if i am correct, can't remember who it was

[E_L]

@peter12 P5 and P6 seem to indicate we can expect a new trial based on this? "The results of these
analyses have led to the approval of a phase-II
clinical study that will be testing Dara in
relapsed/refractory CLL patients."

[Bulder]

There is only one phase 1 study in cll running as far as I can see. So it looks like a new one to come. Nice that dara is being tested in different leukemias.

[E_L]

yes, good news

[Bulder]

The two Duobodies, Peter mentions, are the two presented at CMD recently. There will be INDs H1 next year.

[E_L]

GEN1042 = DuoBody-CD40x4-1BB was mentioned by Genmab in January as a 2018 IND candidate

[Bulder]

Yes but according to CMD it's been delayed it seems.

[E_L]

yes, i am just seeing it, both to H1 2019